A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
Phase 2
Recruiting
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Drug: AP1189, 40 mgDrug: AP1189, 70 mgDrug: AP1189, 100 mgDrug: AP1189 matching placebo
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- SynAct Pharma Aps
- Target Recruit Count
- 240
- Registration Number
- NCT06671054
- Locations
- 🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: AP1189, 80 mgDrug: PlaceboDrug: AP1189, 100 mgDrug: AP1189, 60 mg
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- SynAct Pharma Aps
- Target Recruit Count
- 125
- Registration Number
- NCT05604885
- Locations
- 🇲🇩
Timofei Mosneaga Republican Clinical Hospital, Chișinău, Moldova, Republic of
A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: PlaceboDrug: 100 mg AP1189
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- SynAct Pharma Aps
- Target Recruit Count
- 127
- Registration Number
- NCT05516979
- Locations
- 🇲🇩
Timofei Mosneaga Republican Clinical Hospital, Chișinău, Moldova, Republic of
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
Phase 2
Recruiting
- Conditions
- Severe Proteinuria Due to Idiopathic Membranous NephropathyNephrotic Syndrome Due to Idiopathic Membranous Nephropathy
- Interventions
- Drug: PlaceboDrug: 100 mg AP1189
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- SynAct Pharma Aps
- Target Recruit Count
- 23
- Registration Number
- NCT04456816
- Locations
- 🇩🇰
Aarhus Universitetshospital, Aarhus, Denmark
A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- SynAct Pharma Aps
- Target Recruit Count
- 105
- Registration Number
- NCT04004429
- Locations
- 🇩🇰
Aarhus Universitetshospital, Aarhus, Denmark
🇳🇴Diakonhjemmet Sykehus, Oslo, Norway
© Copyright 2025. All Rights Reserved by MedPath